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Abstract
Pregnancy zone protein (PZP) and plasminogen activator inhibitor type 2 (PAI-2) are two multifunctional
proteins that are elevated in normal pregnancy and numerous other inflammatory states. Both proteins
were originally identified as protease inhibitors, but current evidence supports the notion that they may
also function as modulators of T-helper cells and/or extracellular chaperones. Exacerbated inflammation,
fibrinolytic disturbances and misfolded proteins are all implicated in the pathology of preeclampsia, a
leading cause of maternal and foetal mortality and morbidity. Notably, reduced levels of PZP or PAI-2 are
associated with preeclampsia and clarification of their diverse functions in normal pregnancy could
provide much needed insight regarding the pathogenesis of this disorder. Given that inflammation and
protein misfolding underlie the pathology of a very large number of disorders, the contributions of PZP
and PAI-2 to extracellular proteostasis and immunoregulation could be broad-reaching.
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Abstract
Pregnancy zone protein (PZP) and plasminogen activator inhibitor type 2 (PAI‐2) are two
multifunctional proteins that are elevated in normal pregnancy and numerous other
inflammatory states. Both proteins were originally identified as protease inhibitors, but
current evidence supports the notion that they may also function as modulators of T‐helper
cells and/or extracellular chaperones. Exacerbated inflammation, fibrinolytic disturbances
and misfolded proteins are all implicated in the pathology of preeclampsia, a leading cause
of maternal and foetal mortality and morbidity. Notably, reduced levels of PZP or PAI‐2 are
associated with preeclampsia and clarification of their diverse functions in normal
pregnancy could provide much needed insight regarding the pathogenesis of this disorder.
Given that inflammation and protein misfolding underlie the pathology of a very large
number of disorders, the contributions of PZP and PAI‐2 to extracellular proteostasis and
immunoregulation could be broad‐reaching.
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1. Introduction
Despite their original identification many decades ago, the precise biological importance of
both pregnancy zone protein (PZP; also known as α2‐pregnoglobulin and pregnancy‐
associated α2‐glycoprotein) and plasminogen activator inhibitor type 2 (PAI‐2; also known as
SERPINB2) remains unresolved in the broader biological context. Analysis of the relevant
literature shows a striking disparity between the number of studies of PZP and PAI‐2
compared to the number of studies of other members of the α‐macroglobulin (αM) and
serpin protein families, respectively. It may have been the case that these “poor cousins”
were considered functionally redundant with respect to other αM and serpin family
members, but it is clear that PZP and PAI‐2 blood levels are markedly enhanced in
pregnancy, which supports the conclusion that they have fundamentally important roles
during human gestation. Moreover, their upregulation in a broad range of other
inflammatory states is consistent with PZP and PAI‐2 having generalised roles as
immunomodulators or stress responders. Although PZP and PAI‐2 share no overt structural
similarity (Fig. 1), they share some striking functional similarities and may work together in a
synergistic or complementary manner in extracellular fluids.
2. PZP
a. Structure
PZP belongs to the highly conserved αM protein family which includes a number of protease
inhibitors and complement components. Typically αM family members are formed by one
or more subunit (~180 kDa) which contains a series of macroglobulin domains and a reactive
thioester bond (Fig. 1A). In humans, the PZP gene (12p12‐13, 36 exons) encodes a 1482 bp
transcript which is translated and secreted as a highly glycosylated, disulfide‐linked
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homodimer (360 kDa) that shares extensive amino acid sequence identity (71%) with α2‐
macroglobulin (α2M) (Devriendt et al., 1991). The latter is a homotetramer (720 kDa)
formed by the non‐covalent association of disulfide‐linked dimers. Each subunit of PZP and
α2M comprises a receptor binding domain for the low density lipoprotein receptor‐related
protein (LRP) and a bait region that contains multiple protease cleavage sites (Fig. 1A).
Cleavage of the intramolecular thioester bond of PZP or α2M by reaction with proteases or
small amine molecules results in a major conformational change that causes the proteins to
become more compact, referred to as the transformed conformation. It is well known that
transformation of α2M reveals the cryptic binding site for LRP, on the other hand, while it is
known that transformed PZP (i.e. in complex with proteases) is a ligand of LRP, the
mechanism by which this is achieved is not fully characterised (Chiabrando et al., 2002).
Additional, currently unidentified high affinity receptors for PZP have also been proposed
(Jensen et al., 1988, Chiabrando et al., 2002). Current information on the multi‐domain fold
of PZP is limited; at best, its tertiary structure can be estimated from a low resolution (4.3‐Å)
structure of transformed α2M (Marrero et al., 2012) (Fig. 1A).
b. Expression, activation and turnover
PZP is known to be expressed by a number of different tissue types in humans including the
liver, uterus and brain, and is present in cerebral spinal fluid (CSF), synovial fluid and blood
plasma (Tayade et al., 2005). The majority of plasma PZP is believed to be synthesised by the
liver (Tayade et al., 2005) with plasma levels in both men and women normally < 0.03
mg/ml, but these levels can reportedly increase to ~ 3 mg/mL in some women during
pregnancy (Ekelund and Laurell, 1994). At these levels PZP is one of the most abundant
proteins in blood plasma. This supports the notion that PZP plays an important role in
pregnancy that is not fulfilled by α2M, which is constitutively present in blood plasma at high
3

levels (1.5‐2.0 mg/ml). Nevertheless, the expression of PZP is extremely variable between
individuals and a fraction of women have PZP levels < 0.5 mg/ml throughout otherwise
normal pregnancy (Ekelund and Laurell, 1994). Studies of PZP levels in women administered
contraceptives indicate that PZP expression is controlled by estrogen (Damber et al., 1976),
but alternative promotors are predicted to exist. For example, it has been proposed that
PZP is the acute phase αM in humans (a role performed by α2M in other mammalian species
including rodents) (Sand et al., 1985), which would explain its enhanced levels in a number
of inflammatory disorders (discussed below). Similar to transformed α2M, transformed PZP
is very rapidly cleared from the bloodstream via LRP, which is highly expressed by
hepatocytes in the liver (Gliemann et al., 1986).
c. Biological Functions
PZP was originally described as a protease inhibitor analogous to α2M, but compared to α2M
which can covalently trap a very broad spectrum of proteases, PZP inhibits far fewer
proteases and the mechanism involved is much less efficient (Sand et al., 1985). It has been
suggested that PZP is upregulated under conditions of increased cellular turnover to control
the activities of intracellular proteases such as elastases and chymotrypsin‐like enzymes, but
there is currently little evidence to support this claim and it is feasible that the biological
importance of PZP is related to an alternative role. One suggestion is that during pregnancy
PZP works synergistically with placental protein‐14 (PP14) to inhibit T‐helper 1 (Th1) cell
activation, thereby, protecting the allogenic foetus from maternal immune system attack
(Skornicka et al., 2004) (Fig. 2).

The activities of α2M are uniquely regulated by hypochlorite (an oxidant produced in high
concentrations during inflammation), which induces the dissociation of the native α2M
4

tetramer into dimers that bind to: (i) misfolded proteins (Wyatt et al., 2014); (ii) growth
factors and pro‐inflammatory cytokines (Wu et al., 1998), and (iii) the receptor LRP (Wu et
al., 1997). It is tempting to speculate that PZP (predominately a dimer in biological fluids)
will perform many of the same functions as α2M dimers (Fig. 2). This may be particularly
valid in the case of functions that are largely mediated by hydrophobic interactions such as
holdase‐type chaperone activity, since this property is markedly enhanced on the surface of
α2M dimers and PZP compared to the native α2M tetramer (Jensen et al., 1993, Wyatt et al.,
2014).
3. PAI‐2
a. Structure
PAI‐2 (SERPINB2), a Clade B member of the serine protease inhibitor (serpin) superfamily,
folds into the well‐conserved serpin tertiary structure, including an exposed, flexible peptide
reactive center loop (RCL), which contains the protease recognition site (Fig. 1B). The
SERPINB2 gene (18q21.3, 9 exons) encodes a 1884 bp mRNA which is translated into a 415
amino acid residue monomer (47 kDa) (Ye et al., 1989). PAI‐2 has an inefficient internal
signal sequence and thus tends to accumulate intracellularly (Belin, 1993). However, PAI‐2 is
found as a secreted high molecular weight (HMW) 60 – 70 kDa glycoprotein in biological
fluids including pregnancy plasma (Coolman et al., 2006).

Unlike other serpins, no

pathological outcomes have been linked to PAI‐2 polymerization nor does PAI‐2 convert to a
latent inactive state in the absence of certain cofactors (Lee et al., 2011).
b. Expression and turnover
Under normal physiological conditions PAI‐2 is undetectable in extracellular fluids. In
humans PAI‐2 is acutely upregulated, from negligible levels up to 250 ng/mL in late
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pregnancy (Coolman et al., 2006, Hunt et al., 2009, Guller et al., 2011). PAI‐2 is expressed by
numerous cell types including placental trophoblasts, endothelial cells, monocytes and
macrophages, with large scale upregulation evident in vitro by a wide range of stimulants
associated with inflammatory and/or fibrinolytic conditions (Lee et al., 2011).
Unglycosylated PAI‐2 can be secreted via exosomes by endothelial cells after inflammatory
stimulation in vitro (Boncela et al., 2013) and via microparticles in placental perfusions
(Guller et al., 2011), and this may account for the presence of LMW PAI‐2 in biological fluids
including pregnancy plasma (Booth et al., 1988). Both HMW and LMW PAI‐2 specifically and
efficiently inhibit urokinase plasminogen activator (uPA) and tissue plasminogen activator
(tPA), which are responsible for the proteolytic activation of plasmin from plasminogen, via
an irreversible suicide‐substrate mechanism common to the serpins (Silverman et al., 2004).
Upon inhibition of cellular receptor‐bound uPA, the serpin‐uPA complex is rapidly
endocytosed via receptors of the LDL receptor family, including LRP (the only known
receptor for PZP) and degraded (Al‐Ejeh et al., 2004, Lee et al., 2011).
c. Biological function
In pregnancy extracellular PAI‐2 is believed to protect against premature placental
separation and maintain haemostasis by controlling localized proteolysis and tissue
destruction by counteracting the activity of uPA and tPA (Lee et al., 2011). These target
protease specificities are shared by plasminogen activator inhibitor type 1 (PAI‐1/SERPINE1)
(Lee et al., 2011), even though PAI‐1 and PAI‐2 are phylogeneticially distinct as denoted by
their classification into different serpin clades (Silverman et al., 2004). The overall increased
PAI levels in normal human pregnancy result in decreased overall fibrinolytic activity thus
contributing to the hypercoagulable state associated with pregnancy (Coolman et al., 2006,
Hunt et al., 2009). PAI‐2 is not required for normal murine development, survival or fertility
6

(Dougherty et al., 1999). Considering that Pai2 mRNA is only detected at significant levels in
the murine placenta late in gestation (Dougherty et al., 1999), this limits the usefulness of
murine models of pregnancy‐related PAI‐2 deficiency in humans.

PAI‐2 has also been reported to have a number of other functions that appear to be
independent of protease inhibitory interactions, similar to PZP. This includes modulation of
T‐cell responses (Schroder et al., 2010) and stabilisation of misfolded proteins similar to
holdase‐type chaperones (Lee et al., 2015) (Fig. 2).
4. Disease implications
PZP and PAI‐2 are upregulated in large number of diverse inflammatory conditions where
they are believed to exert cellular protective effects (Thomson and Horne, 1980, Lee et al.,
2011). Here we focus on the reported association of low PZP and PAI‐2 levels with
preeclampsia (Horne et al., 1972, Lee et al., 2011) (Fig. 2). Preeclampsia is a leading cause of
maternal and neonatal morbidity and mortality with currently unknown etiology. The
disorder is characterised by high maternal blood pressure, proteinuria, aberrant placental
development and haemostatic and fibrinolytic disturbances (Hunt et al., 2009, Amaral et al.,
2015). It is known that PZP levels vary markedly between individuals (Ekelund and Laurell,
1994). The reasons for the significantly reduced levels of PAI‐2 in preeclampsia compared to
normal pregnancy are not known (Hunt et al., 2009, Wikstrom et al., 2009), but it possible
that damage to endothelial cells is an important contributing factor.

Systemic inflammation in preeclampsia is much greater than that which occurs in normal
pregnancy (Amaral et al., 2015), and it has been proposed that increased myeloperoxidase
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(the enzyme that generates hypochlorite) in blood plasma and the placenta is an important
source of oxidative stress in preeclampsia (Gandley et al., 2008). An increased PAI‐1/PAI‐2
ratio and placental oxidative stress have been reported as good predictors of preeclampsia
(Wikstrom et al., 2009). Given the known susceptibility of protease inhibitors including PAI‐1
(Baker et al., 1990) and α2M (Deby‐Dupont et al., 1994) to inactivation by reactive oxygen
species, it is plausible that PAI‐2, which is resistant to inactivation by oxidants (Baker et al.,
1990), is an important regulator of fibrinolytic activity under these conditions (Fig. 2).
Currently the effect of oxidation on the protease inhibitory activities of PZP is unknown.

Substantial evidence supports the conclusion that enhanced Th1 cell activity is important in
the pathology of preeclampsia (Amaral et al., 2015). Both α2M and PZP are reported to
potentiate the ability of PP14 to inhibit Th1 cells, but comparatively, PZP appears to be
more efficient at performing this role (Skornicka et al., 2004) (Fig. 2). The enhanced non‐
covalent binding of PZP to PP14 (a lipocalin) is likely to be the result of hydrophobic
interactions. Experiments in PAI‐2 knockout mice indicate that PAI‐2 also plays a role in Th1
cell suppression (Schroder et al., 2010). The mechanism by which this is achieved is not
known, but appears to be unrelated to PAI‐2 protease inhibitory activity and could involve
intracellular functions (Fig. 2).

It has recently been shown that misfolded proteins including the Alzheimer’s disease‐
associated amyloid beta peptide accumulate in the placenta and biological fluids in
preeclampsia (Buhimschi et al., 2014). The toxicity of misfolded proteins is incompletely
characterised, but it is well‐accepted that their accumulation (known to occur in over 40
human disorders) is deleterious. Hypochlorite‐induced dissociation of the native α2M
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tetramer into dimers dramatically enhances its ability to bind to misfolded proteins and
deliver them to LRP for disposal (Wyatt et al., 2014). It is possible that upregulation of PZP is
a strategy to enhance the chaperone capability of biological fluids, but this has yet to be
proven. Furthermore, it is possible that PZP contributes to immunoregulation by non‐
covalently sequestering of a range of other ligands including TNF‐alpha, IL‐2 and IL‐6, which
all preferentially bind to α2M dimers compared to the native α2M tetramer (Wu et al., 1998)
(Fig. 2). It is likely that levels of PZP exceed that of hypochlorite‐induced α2M dimers formed
in vivo. While the modest chaperone activity of PAI‐2 could also contribute to the
stabilisation and disposal of misfolded proteins at the placenta (Fig. 2), this is possibly
overshadowed by the chaperone activity of the highly abundant PZP.
5. Conclusion
Given the upregulation of PZP and PAI‐2 in inflammatory states and their strong association
with normal pregnancy and preeclampsia, it will be important to elucidate their function in
the presence of relevant stressors. We propose that, far from being functionally redundant
α‐macroglobulin and serpin family members, the complementary activities of PZP and PAI‐2
in fibrinolysis, the immune response and extracellular proteostasis are protective in
pregnancy and may have global relevance in inflammation.

9

Figure legends
Fig. 1. Structure and known functional domains of PZP and PAI‐2. (A) Schematic diagram
of human monomeric PZP showing amino acid (aa) residue positions of the signal sequence,
the bait region, the thiol‐ester group and the receptor binding domain. Macroglobulin
domains M1 – M4 are predicted using InterPro (EMBL‐EBI). Multiple N‐glycosylation sites
(Asn54, Asn69, Asn246, Asn392, Asn406, Asn753, Asn875, Asn932, Asn997, Asn1430) are present in PZP
(not shown). PZP monomers (180 kDa) dimerize by disulfide bonds to form the native and
functionally active 360 kDa homodimer. Image shows 3D structure of dimeric α2M based on
the structure of α2M in the transformed conformation PDB ID: 4ACQ (Marrero et al., 2012).
This is currently the best estimate of PZP tertiary structure. (B) Schematic diagram of human
PAI‐2 showing aa residue positions of the internal secretion signal, a unique to PAI‐2
interhelical domain between helices C and D (CD‐loop), the reactive center loop (RCL) which
contains the protease recognition site. Asterisks denote polymorphism sites between two
major variants of PAI‐2; variant A (Asn120, Asn404, Ser413) and B (Asp120, Lys404, Cys413).
Hashtags denote N‐glycosylation sites (Asn75, Asn115, Asn339). Image shows the 3D structure
of PAI‐2 based on PDB ID: 1JRR (Jankova et al., 2001). PAI‐2 conforms to the general tertiary
structure conserved across all known serpins (Silverman et al., 2004). The CD‐loop and RCL
are highly mobile or disordered structures and have not been resolved.
Fig. 2. Potential protective functions of PZP and PAI‐2 in pregnancy. Normal pregnancy is
associated with inflammation and oxidative stress, and elevated levels of PZP and PAI‐2. (1)
Reduced α2M and PAI‐1 protease inhibitory activity occurs in response to hypochlorite
generation, PAI‐2 protease inhibitory activity is resistant to oxidative inactivation and
contributes to the regulation of fibrinolysis. (2) Protein misfolding is enhanced by oxidative
stress, PAI‐2 acts locally as a chaperone for misfolded proteins at the placenta. Dimeric α2M
10

(generated at low centration in response to hypochlorite) and PZP facilitate the clearance of
misfolded proteins and pro‐inflammatory cytokines. (3) PZP (in concert with PP14) and PAI‐2
have inhibitory effects on Th1 cells, although the mechanisms involved remain enigmatic.
Comparatively, the effect of PZP on Th1 cells is greater than that of α2M. Low levels of PZP
and PAI‐2 could allow inflammation to become exacerbated which drives placental
dysfunction and preeclampsia.

Acknowledgements
A.R.W is grateful to the National Health and Medical Research Council for financial support.

References
Al‐Ejeh, F., Croucher, D.Ranson, M. 2004. Kinetic analysis of plasminogen activator inhibitor type‐2:
urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp. Cell
Res. 297, 259‐271.
Amaral, L. M., Cunningham, M. W., Cornelius, D. C.LaMarca, B. 2015. Preeclampsia: long‐term
consequences for vascular health. Vasc. Health Risk Manag. 11, 403‐415.
Baker, M. S., Green, S. P., Goss, N., Katrantzis, M.Doe, W. F. 1990. Plasminogen activator inhibitor 2
(PAI‐2) is not inactivated by exposure to oxidants which can be released from activated
neutrophils. Biochem. Biophys. Res. Commun. 166, 993‐1000.
Belin, D. 1993. Biology and facultative secretion of plasminogen activator inhibitor‐2. Thromb.
Haemost. 70, 144‐147.
Boncela, J., Przygodzka, P., Wyroba, E., Papiewska‐Pajak, I.Cierniewski, C. S. 2013. Secretion of
SerpinB2 from endothelial cells activated with inflammatory stimuli. Exp. Cell Res. 319, 1213‐
1219.
Booth, N. A., Reith, A.Bennett, B. 1988. A plasminogen activator inhibitor (PAI‐2) circulates in two
molecular forms during pregnancy. Thromb. Haemost. 59, 77‐79.
Buhimschi, I. A., Nayeri, U. A., Zhao, G., Shook, L. L., Pensalfini, A., Funai, E. F., Bernstein, I. M., Glabe,
C. G.Buhimschi, C. S. 2014. Protein misfolding, congophilia, oligomerization, and defective
amyloid processing in preeclampsia. Sci. Transl. Med. 6, 245ra292.
Chiabrando, G. A., Vides, M. A.Sanchez, M. C. 2002. Differential binding properties of human
pregnancy zone protein‐ and alpha2‐macroglobulin‐proteinase complexes to low‐density
lipoprotein receptor‐related protein. Arch. Biochem. Biophys. 398, 73‐78.
Coolman, M., de Groot, C. J., Steegers, E. A., Geurts‐Moespot, A., Thomas, C. M., Steegers‐
Theunissen, R. P.Sweep, F. C. 2006. Concentrations of plasminogen activators and their
inhibitors in blood preconceptionally, during and after pregnancy. Eur. J. Obstet. Gynecol.
Reprod. Biol. 128, 22‐28.

11

Damber, M. G., von Schoultz, B., Solheim, F.Stigbrand, T. 1976. A quantitative study of the pregnancy
zone protein in sera of woman taking oral contraceptives. Am. J. Obstet. Gynecol. 124, 289‐
292.
Deby‐Dupont, G., Croisier, J. L., Camus, G., Brumioul, D., Mathy‐Hartert, M., Sondag, D., Deby,
C.Lamy, M. 1994. Inactivation of alpha(2)‐Macroglobulin by Activated Human
Polymorphonuclear Leukocytes. Mediators Inflamm. 3, 117‐123.
Devriendt, K., Van den Berghe, H., Cassiman, J.‐J.Marynen, P. 1991. Primary structure of pregnancy
zone protein. Molecular cloning of a full‐length PZP cDNA clone by the polymerase chain
reaction. Biochim. Biophys. Acta. 1088, 95‐103.
Dougherty, K. M., Pearson, J. M., Yang, A. Y., Westrick, R. J., Baker, M. S.Ginsburg, D. 1999. The
plasminogen activator inhibitor‐2 gene is not required for normal murine development or
survival. Proc. Natl. Acad. Sci. USA. 96, 686‐691.
Ekelund, L.Laurell, C. B. 1994. The pregnancy zone protein response during gestation: a metabolic
challenge. Scand. J. Clin. Lab. Invest. 54, 623‐629.
Gandley, R. E., Rohland, J., Zhou, Y., Shibata, E., Harger, G. F., Rajakumar, A., Kagan, V. E., Markovic,
N.Hubel, C. A. 2008. Increased myeloperoxidase in the placenta and circulation of women with
preeclampsia. Hypertension. 52, 387‐393.
Gliemann, J., Moestrup, S., Henning Jensen, P., Sottrup‐Jensen, L., Busk Andersen, H., Munck
Petersen, C.Sonne, O. 1986. Evidence for binding of human pregnancy zone protein‐
proteinase complex to alpha 2‐macroglobulin receptors. Biochim. Biophys. Acta. 883, 400‐406.
Guller, S., Tang, Z., Ma, Y. Y., Di Santo, S., Sager, R.Schneider, H. 2011. Protein composition of
microparticles shed from human placenta during placental perfusion: Potential role in
angiogenesis and fibrinolysis in preeclampsia. Placenta. 32, 63‐69.
Horne, C. H., Briggs, J. D., Howie, P. W.Kennedy, A. C. 1972. Serum ‐macroglobulins in renal disease
and preeclampsia. J. Clin. Pathol. 25, 590‐593.
Hunt, B. J., Missfelder‐Lobos, H., Parra‐Cordero, M., Fletcher, O., Parmar, K., Lefkou, E.Lees, C. C.
2009. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women
undergoing uterine artery Doppler screening at 23 weeks. J. Thromb. Haemost. 7, 955‐961.
Jankova, L., Harrop, S. J., Saunders, D. N., Andrews, J. L., Bertram, K. C., Gould, A. R., Baker, M.
S.Curmi, P. M. 2001. Crystal structure of the complex of plasminogen activator inhibitor 2 with
a peptide mimicking the reactive center loop. J. Biol. Chem. 276, 43374‐43382.
Jensen, P. E., Hagglof, E. M., Arbelaez, L. F., Stigbrand, T.Shanbhag, V. P. 1993. Comparison of
conformational changes of pregnancy zone protein and human alpha 2‐macroglobulin, a study
using hydrophobic affinity partitioning. Biochim. Biophys. Acta. 1164, 152‐158.
Jensen, P. H., Moestrup, S. K., Sottrup‐Jensen, L., Petersen, C. M.Gliemann, J. 1988. Receptors for
alpha 2‐macroglobulin‐ and pregnancy zone protein‐proteinase complexes in the human
placental syncytiotrophoblast. Placenta. 9, 463‐477.
Lee, J. A., Cochran, B. J., Lobov, S.Ranson, M. 2011. Forty years later and the role of plasminogen
activator inhibitor type 2/SERPINB2 is still an enigma. Semin. Thromb. Hemost. 37, 395‐407.
Lee, J. A., Yerbury, J. J., Farrawell, N., Shearer, R. F., Constantinescu, P., Hatters, D. M., Schroder, W.
A., Suhrbier, A., Wilson, M. R., Saunders, D. N., et al. 2015. SerpinB2 (PAI‐2) Modulates
Proteostasis via Binding Misfolded Proteins and Promotion of Cytoprotective Inclusion
Formation. PLoS One. 10, e0130136.
Marrero, A., Duquerroy, S., Trapani, S., Goulas, T., Guevara, T., Andersen, G. R., Navaza, J., Sottrup‐
Jensen, L.Gomis‐Rüth, F. X. 2012. The Crystal Structure of Human α2‐Macroglobulin Reveals a
Unique Molecular Cage. Angew. Chem. Int. Ed. 51, 3340‐3344.
Sand, O., Folkersen, J., Westergaard, J. G.Sottrup‐Jensen, L. 1985. Characterization of human
pregnancy zone protein. Comparison with human alpha 2‐macroglobulin. J. Biol. Chem. 260,
15723‐15735.

12

Schroder, W. A., Le, T. T., Major, L., Street, S., Gardner, J., Lambley, E., Markey, K., Macdonald, K. P.,
Fish, R. J., Thomas, R., et al. 2010. A Physiological Function of Inflammation‐Associated
SerpinB2 Is Regulation of Adaptive Immunity. J. Immunol. 184, 2663‐2670.
Silverman, G. A., Whisstock, J. C., Askew, D. J., Pak, S. C., Luke, C. J., Cataltepe, S., Irving, J. A.Bird, P. I.
2004. Human clade B serpins (ov‐serpins) belong to a cohort of evolutionarily dispersed
intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis. Cell.
Mol. Life Sci. 61, 301‐325.
Skornicka, E. L., Kiyatkina, N., Weber, M. C., Tykocinski, M. L.Koo, P. H. 2004. Pregnancy zone protein
is a carrier and modulator of placental protein‐14 in T‐cell growth and cytokine production.
Cell. Immunol. 232, 144‐156.
Tayade, C., Esadeg, S., Fang, Y.Croy, B. A. 2005. Functions of alpha 2 macroglobulins in pregnancy.
Mol. Cell. Endocrinol. 245, 60‐66.
Thomson, A. W.Horne, C. H. 1980. Biological and clinical significance of pregnancy‐associated
alpha2‐glycoprotein (alpha/‐PAG)‐a review. Invest. Cell. Pathol. 3, 295‐309.
Wikstrom, A. K., Nash, P., Eriksson, U. J.Olovsson, M. H. 2009. Evidence of increased oxidative stress
and a change in the plasminogen activator inhibitor (PAI)‐1 to PAI‐2 ratio in early‐onset but
not late‐onset preeclampsia. Am. J. Obstet. Gynecol. 201, 597 e591‐598.
Wu, S. M., Boyer, C. M.Pizzo, S. V. 1997. The binding of receptor‐recognized alpha2‐macroglobulin to
the low density lipoprotein receptor‐related protein and the alpha2M signaling receptor is
decoupled by oxidation. J. Biol. Chem. 272, 20627‐20635.
Wu, S. M., Patel, D. D.Pizzo, S. V. 1998. Oxidized alpha2‐macroglobulin (alpha2M) differentially
regulates receptor binding by cytokines/growth factors: implications for tissue injury and
repair mechanisms in inflammation. J. Immunol. 161, 4356‐4365.
Wyatt, A. R., Kumita, J. R., Mifsud, R. W., Gooden, C. A., Wilson, M. R.Dobson, C. M. 2014.
Hypochlorite‐induced structural modifications enhance the chaperone activity of human
alpha2‐macroglobulin. Proc. Natl. Acad. Sci. USA. 111, E2081‐2090.
Ye, R. D., Ahern, S. M., Le Beau, M. M., Lebo, R. V.Sadler, J. E. 1989. Structure of the gene for human
plasminogen activator inhibitor‐2. The nearest mammalian homologue of chicken ovalbumin.
J. Biol. Chem. 264, 5495‐5502.

13

Figure 1

Figure 2

14

